Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers

Journal of Analytical Toxicology

Volumn 37, Issue 1, 2013, Pages 11-16

  Gorelick, David A ^a   Goodwin, Robert S ^a   Schwilke, Eugene ^a   Schwope, David M ^a   Darwin, William D ^a   Kelly, Deanna L ^b   McMahon, Robert P ^b   Liu, Fang ^b   Ortemann Renon, Catherine ^c   Bonnet, Denis ^c   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL;

ADULT; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG TOLERANCE; HEART RATE; HUMAN; MALE; PSYCHOSIS; SEIZURE; SYSTOLIC BLOOD PRESSURE; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; CANNABINOIDS; CANNABIS; CHROMATOGRAPHY, GAS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HUMANS; MALE; MARIJUANA SMOKING; MASS SPECTROMETRY; MIDDLE AGED; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; YOUNG ADULT;

CANNABIS;

EID: 84872770426     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bks081     Document Type: Article

References (27)

1. United Nations Office on Drugs and Crime. (2008) 2008 World Drug Report. Vienna, Austria, pp. 310.
2. Cotter, J. (2009) Efficacy of crude marijuana and synthetic delta-9-tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: A systematic literature review. Oncology Nursing Forum, 36, 345-352.
3. Turcotte, D., Le Dorze, J.-A., Esfahani, F., Frost, E., Gomori, A., Namaka, M. (2010) Examining the roles of cannabinoids in pain and other therapeutic indications: A review. Expert Opinion on Pharmacotherapy, 11, 17-31.
4. André, C., Jaber-Filho, J.A., Bento, R.M., Damasceno, L.M., Aquino-Neto, F.R. (2006) Delirium following ingestion of marijuana present in chocolate cookies. CNS Spectrums, 11, 262-264.
5. Chaudry, H.R., Moss, H.B., Bashir, A, Suliman, T. (1991) Cannabis psychosis following bhang ingestion. British Journal of Addiction, 86, 1075-1081.
6. Gorter, RW, Butorac, M., Cobian, E.P., van der Sluis, W. (2005) Medical use of cannabis in the Netherlands. Neurology, 64, 917-919.
7. Lynch, M.E., Young, J., Clark, A.J. (2006) A case series of patients using medicinal marihuana for management of chronic pain under the Canadian marihuana medical access regulations. Journal of Pain and Symptom Management, 32, 497-501.
8. Lynch, M.E., Young, J., Clark, A.J. (2006) Marinol. In Physicians desk reference, 60th edition. Thomson, Montvale, NJ, pp. 3334-3336.
9. Frank, I.M., Lessin, P.J., Tyrrell, E.D., Hahn, P.M., Szara, S. (1976) Acute and cumulative effects of marihuana smoking in hospitalized subjects: A 36-day study. In Braude, M.C., Szara, S. (eds.), The pharmacology of marihuana, Raven Press, New York, NY, pp. 673-680.
10. Mendelson, J.H., Babor, T.F., Kuehnle, J.C., Rossi, A.M., Bernstein, J.G., Mello, N.K. et al. (1976) Behavioral and biologic aspects of marijuana use. Annals of the New York Academy of Sciences, 282, 186-210.
11. Jones, R.T., Benowitz, N.L., Herning, R.I. (1981) Clinical relevance of cannabis tolerance and dependence. Journal of Clinical Pharmacology, 21, 143S-152S.
12. Jones, R.T., Benowitz, N. (1976) The 30-day trip-Clinical studies of cannabis tolerance and dependence. In Braude, M.C., Szara, S. (eds.), The pharmacology of marijuana, Raven Press, New York, NY, pp. 627-643.
13. Jones, R.T., Benowitz, N., Bachman, J. (1976) Clinical studies of cannabis tolerance and dependence. Annals of the New York Academy of Sciences, 282, 221-239.
14. Haney, M., Ward, A.S., Comer, S.D., Foltin, R.W., Fischman, M.W. (1999) Abstinence symptoms following oral THC administration to humans. Psychopharmacology, 141, 385-394.
15. Bedi, G., Foltin, R., Gunderson, E., Rabkin, J., Hart, C., Comer, S. et al. (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: A controlled laboratory study. Psychopharmacology, 212, 675-686.
16. Gorelick, D.A., Goodwin, R.S., Schwilke, E., Schwope, D.M., Darwin, W.D., Kelly, D.L. et al. (2011) Antagonist-elicited cannabis withdrawal in humans. Journal of Clinical Psychopharmacology, 31, 603-612.
17. Huestis, M.A., Gorelick, D.A., Heishman, S.J., Preston, K.L., Nelson, R.A., Moolchan, E.T. et al. (2001) Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry, 58, 322-330.
18. Lowe, R.H., Karschner, E.L., Schwilke, E.W., Barnes, A.J., Huestis, M.A. (2007) Simultaneous quantification of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC), and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. Journal of Chromatography A, 1163, 318-327.
19. Jones, R.T. (2002) Cardiovascular system effects of marijuana. Journal of Clinical Pharmacology, 42, 58S-63S.
20. Kirk, J.M., de Wit, H. (1999) Responses to oral delta-9-tetrahydrocannabinol in frequent and infrequent marijuana users. Pharmacology Biochemistry and Behavior, 63, 137-142.
21. Ponto, L.L., O'Leary, D.S., Koeppel, J., Block, R.I., Watkins, G.L., Richmond, J.C. et al. (2004) Effect of acute marijuana on cardiovascular function and central nervous system pharmacokinetics of [(15)O]water: Effect in occasional and chronic users. Journal of Clinical Pharmacology, 44, 751-766.
22. Lindgren, J.E., Ohlsson, A., Agurell, S., Hollister, L., Gillespie, H. (1981) Clinical effects and plasma levels of delta-9-tetrahydrocannabinol (delta-9-THC) in heavy and light users of cannabis. Psychopharmacology, 74, 208-212.
23. Huestis, M.A., Boyd, S.J., Heishman, S.J., Preston, K.L., Bonnet, D., Le Fur, G. et al. (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berlin), 194, 505-515.
24. Gorelick, D.A., Heishman, S.J., Preston, K.L., Nelson, R.A., Moolchan, E.T., Huestis, M.A. (2006) The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. American Heart Journal, 151, 751-754.
25. Gonzalez, S., Cebeira, M., Fernandez-Ruiz, J. (2005) Cannabinoid tolerance and dependence: A review of studies in laboratory animals. Pharmacology Biochemistry and Behavior, 81, 300-318.
26. Hirvonen, J., Goodwin, R.S., Li, C.T., Terry, G.E., Zoghbi, S.S., Morse, C. et al. (2012) Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17, 642-649.
27. Agnew, H., Webb, W., Williams, R. (1966) The first night effect: An EEG study of sleep. Psychophysiology, 2, 263-266.